What Healthcare Investment Bankers Do

Introduction

Healthcare investment banking sits at the intersection of the largest sector in the US economy and some of the most complex transactions in finance. With healthcare spending exceeding $4.5 trillion annually (roughly 18% of US GDP), the deal activity is enormous: biopharma M&A alone exceeded $138 billion across 129 deals in 2025, and healthcare private equity deal value set a record at over $190 billion. But it is not just the size that makes healthcare IB distinctive. It is the nature of the work itself.

Unlike generalist bankers who can apply a common analytical toolkit across industries, healthcare bankers operate in a world where an FDA decision can destroy $10 billion in market cap overnight, where the "product" might be a molecule that has never generated revenue, and where deal structures routinely include mechanisms (contingent value rights, regulatory milestone earnouts, reverse termination fees) that barely exist elsewhere. This article breaks down what healthcare investment bankers actually do, how their work differs from other coverage groups, and why the domain expertise creates both career moats and interview barriers.

Healthcare investment banking encompasses five major work streams. While the first two (M&A advisory and capital markets) exist in every coverage group, the remaining three are either unique to healthcare or take on a fundamentally different character in this sector.

M&A Advisory

M&A advisory is the primary revenue driver for healthcare banking groups, and it spans a remarkable range of transaction sizes and types. At the top end, mega-deals like Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies and Novartis's $12 billion purchase of Avidity Biosciences reshape entire therapeutic categories. At the lower end, middle-market healthcare services M&A (physician practices, ambulatory surgery centers, behavioral health platforms) generates consistent deal flow through the platform and add-on consolidation model.

Strategic Alternatives Review

An engagement where an investment bank evaluates all available options for a company, including outright sale, partial sale, joint venture, recapitalization, IPO, or remaining independent. In healthcare, these are particularly common for clinical-stage biotech companies approaching binary catalysts (Phase III data readouts, FDA advisory committee meetings) where the value gap between success and failure creates strategic urgency.

Healthcare M&A advisory includes both sell-side and buy-side mandates:

What makes healthcare M&A advisory distinctive is the regulatory overlay on every transaction. A typical healthcare deal must clear not just standard antitrust review, but potentially FTC scrutiny specific to healthcare market concentration, HSR filing with extended review timelines, and state-level regulatory approvals (certificate of need, change of ownership). Closing timelines of 6-12+ months are common, and the deal structure must account for this execution risk through deal certainty mechanisms like reverse termination fees and ticking fees.

Healthcare M&A processes also run differently than in other sectors. Sell-side biopharma processes often involve limited auctions with a small number of qualified strategic buyers rather than broad market canvasses, because only a handful of pharma companies have the commercial infrastructure to monetize a specific therapeutic asset. Due diligence takes longer and involves layers that do not exist elsewhere: scientific due diligence on clinical data packages, regulatory due diligence on FDA interactions and approval pathways, intellectual property due diligence on patent portfolios and freedom-to-operate opinions, and commercial due diligence on market access and payer dynamics. The healthcare banker coordinates this multi-layered process while managing buyer engagement and maintaining competitive tension.

Capital Markets: ECM and DCM

Healthcare groups work closely with equity capital markets (ECM) and debt capital markets (DCM) product groups on capital raising transactions. Healthcare represented nearly 40% of follow-on offering supply in 2025, reflecting the sector's capital-intensive nature.

ECM in healthcare takes on a unique character because of biotech. Pre-revenue companies that burn $50-200 million annually in R&D need to repeatedly access equity markets. The transaction types include:

DCM in healthcare is equally active. Big Pharma companies routinely issue investment-grade debt to fund acquisitions: when AbbVie acquired Allergan for $63 billion, it raised over $30 billion in the bond market. Healthcare services companies (often PE-backed) access leveraged loan and high-yield bond markets to fund roll-up acquisitions. The healthcare coverage banker's role is to advise on timing, sizing, and structure while coordinating with the DCM desk on execution.

Licensing and Partnering Transactions

This is where healthcare IB diverges most sharply from other coverage groups. Licensing deals are a major component of the biopharma transaction landscape, with over $250 billion announced across 516 deals in 2025 alone.

Licensing Deal (In-Licensing / Out-Licensing)

A transaction where one company grants another the rights to develop, manufacture, or commercialize a drug, biologic, or technology, typically in exchange for upfront payments, milestone payments, and royalties. In-licensing means acquiring rights; out-licensing means granting them. These deals are a core work product for healthcare bankers, distinct from traditional M&A.

Licensing structures vary enormously. A small upfront payment of $50-200 million paired with $1-5 billion in development and commercial milestones is typical. Bristol Myers Squibb's June 2025 deal with BioNTech carried $1.5 billion upfront with up to $7.6 billion in milestones, totaling $11.1 billion in potential value. These are not simple transactions: the banker must model probability-weighted milestone scenarios, negotiate the risk allocation between licensor and licensee, and structure economics that work for both parties given deep uncertainty about clinical outcomes.

Restructuring and Strategic Defense

Healthcare restructuring is a growing work stream driven by two forces: pharma companies facing severe patent cliffs and biotech companies that have failed pivotal clinical trials. When a biotech's lead asset fails in Phase III, the equity can lose 60-80% of its value overnight. The board needs immediate advice on its options: wind down operations and return cash to shareholders, pivot development resources to remaining pipeline candidates, sell the company's residual assets to a strategic acquirer, or explore a reverse merger with another clinical-stage company. These situations require a banker who can value remaining pipeline assets under extreme uncertainty and run an accelerated process on a compressed timeline.

Healthcare companies are also increasingly targets of shareholder activism. Activists have targeted pharma companies for underperforming pipeline R&D (arguing the company should return capital or pursue a sale), medtech conglomerates for trading at a discount to the sum of their parts (arguing for spin-offs or divestitures), and biotech companies sitting on large cash positions after failed trials (arguing for liquidation or a strategic combination). Healthcare bankers advise boards on these situations, building detailed analyses comparing standalone value, sale value, and restructuring alternatives.

Spin-offs and carve-outs represent another important transaction type. When a diversified pharma or medtech company determines that a non-core business unit is worth more under separate ownership, it engages healthcare bankers to advise on the separation. J&J's separation of its consumer health business into Kenvue (via a $3.8 billion IPO followed by a full spin-off) and BD's announced $17.5 billion sale of its bioprocessing and diagnostics assets to Waters Corporation are recent examples. These transactions require rebuilding standalone financials from divisional reporting, allocating shared costs, and modeling the operational and tax implications of separation.

Beyond the specific work streams, healthcare transactions have structural characteristics that set them apart from deals in other sectors. Understanding these differences is critical for anyone preparing for healthcare group interviews.

The result is that healthcare bankers need a broader analytical toolkit than their peers in other groups. A generalist banker can value most companies with a standard DCF and trading comps. A healthcare banker needs to know when to use rNPV (pre-revenue biotech), sum-of-the-parts with product-level DCFs (pharma), procedure-volume-driven revenue builds (medtech), or payer-mix-adjusted EBITDA (services). The sub-sector map in the next article breaks down which frameworks apply where.

What ultimately sets healthcare investment banking apart is the depth of domain expertise required. Healthcare bankers need working knowledge across three domains that have no parallel in other coverage groups.

Scientific literacy. You need to understand enough biology and pharmacology to evaluate a drug's mechanism of action, assess the significance of clinical trial endpoints, and hold credible conversations with biotech management teams. You do not need a PhD, but you need to know the difference between a surrogate endpoint and a primary endpoint, why a p-value of 0.04 matters, and what it means when a drug shows a "statistically significant but clinically meaningless" effect.

Regulatory expertise. FDA approval pathways, patent law, regulatory exclusivity periods, expedited designations, and the interplay between them all directly impact valuation and deal structure. When you are modeling a pharma company's sum-of-the-parts, the difference between an NCE with 5 years of data exclusivity and an orphan drug with 7 years of market exclusivity changes the revenue projection by years and billions of dollars.

Reimbursement economics. Who pays for healthcare products and services, and how much they pay, is arguably the single most important driver of company value. Payer mix (the split between commercial insurance, Medicare, and Medicaid) can drive a 40-60% difference in EBITDA multiples between otherwise identical healthcare services companies. Drug pricing through the gross-to-net waterfall can reduce a drug's list price revenue by 30-70%.

In practice, these three domains do not exist in isolation. They compound. Consider a healthcare banker building a sum-of-the-parts valuation for a mid-cap pharma company with three commercial products and two pipeline assets. For each commercial product, the banker must know the patent and regulatory exclusivity expiration dates (regulatory expertise), estimate the revenue trajectory including the gross-to-net waterfall and the rate at which generics or biosimilars will erode post-LOE revenue (reimbursement economics), and project how upcoming clinical data from label expansion trials might extend the product's commercial life (scientific literacy). For the pipeline assets, the banker applies probability-of-success estimates by phase and therapeutic area (scientific literacy), models the FDA timeline including any expedited pathway designations (regulatory expertise), and builds a revenue projection based on addressable patient population, pricing, and expected payer coverage decisions (reimbursement economics). Each product slice in the model requires all three knowledge domains working together. A generalist banker who understands DCF mechanics but lacks these domain-specific inputs would produce a model that looks technically correct but is analytically empty.

This domain knowledge is also what creates exceptional exit opportunities. Healthcare PE firms, biotech hedge funds, pharma corporate development teams, and life science VCs all seek professionals who combine financial modeling skills with healthcare domain expertise. The investment in learning the sector pays compounding returns throughout a career.